Educational reference · not currently offered at Delight

Exosome Therapy in Seoul

Q: Is exosome FDA-approved?

No. FDA has approved ZERO exosome products for any indication. Globally registered as COSMETIC ingredient. FDA issued Public Safety Notification (Dec 2019) and warning letters in 2024-2025 targeting IV exosome operators. 'FDA-approved exosome' marketing is factually incorrect.

Q: Is exosome the same as stem cell therapy?

No. Exosomes are 30-150 nm extracellular vesicles — cell-free byproducts of MSC culture, NOT live cells. Regulatory categories and mechanisms differ. Calling exosome 'stem cell therapy' is biologically and regulatorily misleading.

Q: Do you offer IV exosome?

No. We do not offer exosome in any form. IV exosome has no therapeutic evidence base, FDA enforcement actions, and a documented bacterial infection cluster. We would not recommend it at any clinic.

Q: Does exosome replace minoxidil and finasteride?

No. First-line AGA is minoxidil 5% + finasteride 1 mg (Chen 2020). Exosome scalp adjunct is preliminary (non-inferior to PRP, 'data lacking' per Kost 2022). Exosome sits on top of established therapy, never replaces it.

Q: Exosome vs PRP?

PRP is autologous (your own blood). Exosome is allogeneic (donor MSC culture). Estupiñán 2025 split-face: exosome NON-INFERIOR to PRP, not superior. Counterfeit Korean exosome circulates — ask for direct-distribution documentation if pursuing elsewhere.

Q: One-trip exosome course?

Single-session skin protocols viable in a 3-day trip. Full 5-session scalp AGA course requires monthly intervals × 5 months — NOT single-trip and cannot be compressed.

Q: Most serious risks?

(1) IV / systemic injection sterility — FDA enforcement + bacterial infection cluster. (2) Hypersensitivity to MSC-derived material. (3) Counterfeit product without verifiable sterility.

Q: Why cosmetic registration, not drug?

No exosome product has completed the multi-phase RCT efficacy / safety data required for drug approval. Cosmetic pathway permits topical application without that data. Until drug-grade RCT data is filed, exosome remains cosmetic-pathway.

Q: Realistic improvement?

Modest, on top of baseline therapy. Acne scars: 12.6 percentage point delta vs control (Kwon 2020). Photoaging: GAIS improvement (Park 2023, subjective scale). Hair: non-inferior to PRP. We do NOT use 'regrow' / 'cure' / 'permanent' / 'miracle' language.

Q: Safety — systematic review evidence?

Topical safety signal is more favorable than IV. Total exposed-patient count is small. Queen & Avram 2024: 9 alopecia studies, 125 patients, 10 serious adverse events across broader dermatology literature.

Exosome therapy uses cell-free extracellular vesicles studied for skin rejuvenation and hair loss, but no FDA-approved or MFDS-approved exosome drug exists, and Delight Dermatology does NOT currently offer this modality. Exosomes are 30-150 nm vesicles secreted by mesenchymal stromal cells — cell-free, NOT stem cells. Globally they are registered as COSMETICS in Korea, the US, and the EU. Clinical evidence is preliminary, effect sizes modest, long-term safety not characterized. This page exists so patients who have read about exosome therapy elsewhere can make informed decisions.

Board-Certified

Dermatologist

AAD International Fellow

IFAAD

FDA-cleared

Where applicable

MFDS-registered

Korean MoH&W

Reviewed personally by Dr. SangYoul Yun

Board-certified Dermatologist · AAD International Fellow (IFAAD) · IFAAD-verified

Overview

Educational overview of exosome therapy — what the evidence supports, regulatory status, and why we do not currently offer this modality at Delight Dermatology.

Best for

Educational page — Delight does NOT offer exosome therapy in any form.
Common reasons patients ask: AGA hair-loss adjunct, post-laser recovery, photoaging, acne scars, melasma
Common misconceptions: 'FDA-approved' (no), 'stem cell therapy' (no — cell-free vesicles), 'IV is safe and effective' (no, documented safety concerns), 'replaces minoxidil + finasteride' (no — first-line per Chen 2020)
International patients wanting honest framing on what evidence supports vs what cosmetic marketing overclaims

Suited for

Delight does NOT offer exosome therapy. If seeking it, consult another clinic.
AGA: first-line is minoxidil 5% + finasteride 1 mg (Chen 2020). Microneedling + minoxidil outperforms minoxidil alone (Abdi 2023). Exosome scalp adjunct is preliminary.
Post-procedure recovery: published exosome adjunct (Kwon 2020 acne scars n=25; Park 2023 photoaging n=28) shows modest effect sizes — not dramatic.
Patients seeking information on regulatory status or alternative-clinic selection — we discuss at consult but do not offer the procedure.

Duration: Not applicable — modality not offered at Delight
Sessions: Not applicable
Downtime: Not applicable
Peak result: Published evidence ceiling (other clinics): modest skin adjunct effect at month 2-3; preliminary hair evidence non-inferior to PRP

Timeline

Day 0
Effects dominated by the paired procedure (laser / microneedling / RF microneedling), not the exosome topical. No systemic effect (no IV route).
Day 1-3
Paired-procedure erythema peaks; exosome topical does not eliminate but may modestly reduce recovery duration per RCT secondary endpoints.
Skin course midpoint
Modest texture and tone improvement at month 1-2 paired with fractional CO2 or RF microneedling.
End of course
Skin: Kwon 2020 documented 32.5% improvement vs 19.9% control (acne scars). Modest effect sizes, NOT dramatic before-and-after.
Scalp AGA
Any hair-density change reflects baseline minoxidil + finasteride, NOT exosome in isolation. Realistic ceiling: non-inferior to PRP.
Long-term
AGA is chronic — stopping minoxidil + finasteride resumes miniaturization within 3-6 months. Exosome does NOT change this biology.
Honest framing
Modest effect sizes. We do NOT use 'regrow' / 'cure' / 'permanent' / 'guaranteed' / 'miracle' / 'stem cell magic' language.

Devices

Exosome — educational reference only (NOT offered at Delight)

(not applicable — Delight does not currently offer exosome therapy)COSMETIC ingredient (Korea / US / EU). NOT a drug, NOT therapeutic biologic, NOT FDA-approved, NOT MFDS-approved. FDA Public Safety Notification issued Dec 2019.

Key specs

: Extracellular vesicles 30-150 nm; cell-free, NOT stem cell therapy
Mechanism: paracrine vesicle signaling — not cell engraftment
Skin RCTs (small): Kwon 2020 acne scars · Park 2023 photoaging · Wang 2022 melasma
Hair evidence preliminary: Estupiñán 2025 non-inferior to PRP · Kost 2022 'data lacking'
: First-line AGA is minoxidil + finasteride (Chen 2020) — exosome is ADJUNCT if used at all
: IV exosome carries documented safety concerns. We do not recommend it.

Process

01
Educational page only. Delight does NOT offer exosome therapy. See our other procedure pages (laser, microneedling, RF microneedling, biostimulators).
02
What exosome is: 30-150 nm extracellular vesicles secreted by MSCs, carrying microRNA / mRNA / growth-factor cargo. CELL-FREE — NOT live cells. Calling it 'stem cell therapy' is biologically incorrect.
03
Regulatory status: COSMETIC ingredient in Korea / US / EU. Not approved as drug or therapeutic biologic in any jurisdiction. FDA issued Public Safety Notification on Stem Cell and Exosome Products (Dec 2019).
04
Evidence base (small): Kwon 2020 RCT n=25 — 32.5% vs 19.9% acne-scar improvement (p<0.01). Park 2023 RCT n=28 — photoaging GAIS p=0.005. Estupiñán 2025 — non-inferior to PRP (not superior). Kost 2022 — 'data lacking' for exosome hair loss.
05
First-line AGA is NOT exosome — minoxidil + finasteride per Chen 2020. Exosome scalp adjunct sits on top of established therapy if pursued, never replaces it.
06
IV exosome carries documented safety concerns — FDA enforcement + bacterial infection cluster. We do not recommend it at any clinic.

“Injectables and energy devices are performed by physicians — never delegated to non-physician staff. The clinic is led by a board-certified dermatologist.”
— Dr. SangYoul Yun · Clinic Director · Board-Certified Dermatologist · AAD IFAAD

Aftercare

Day 0
Aftercare governed by paired procedure, not exosome topical. Skin: bland emollient + SPF 50+, avoid heat / sweat / alcohol 24-48h. Scalp: no shampoo 12h, continue minoxidil from Day 2.
Day 1-3
Continue emollient + SPF. Avoid retinoids / AHA / BHA / vitamin C / BPO for 5-7 days. Scalp: resume minoxidil Day 2, continue finasteride.
Day 3-14
Paired-procedure healing completes. Take-home exosome (if dispensed) applied per protocol. Resume normal skincare after Day 7-10 if tolerated. Strict daily SPF 50+ continues.
Weeks 2-12
Skin: next session 4-6 weeks. Scalp: next session 1 month. Continue baseline minoxidil + finasteride. Report scalp inflammation, persistent erythema, or atypical reactions.
Long-term
AGA is chronic — minoxidil + finasteride must be maintained indefinitely. Exosome does NOT change this biology. Identify home-country dermatologist for ongoing AGA monitoring.

FAQ

Is exosome FDA-approved?

No. FDA has approved ZERO exosome products for any indication. Globally registered as COSMETIC ingredient. FDA issued Public Safety Notification (Dec 2019) and warning letters in 2024-2025 targeting IV exosome operators. 'FDA-approved exosome' marketing is factually incorrect.

Is exosome the same as stem cell therapy?

No. Exosomes are 30-150 nm extracellular vesicles — cell-free byproducts of MSC culture, NOT live cells. Regulatory categories and mechanisms differ. Calling exosome 'stem cell therapy' is biologically and regulatorily misleading.

Do you offer IV exosome?

No. We do not offer exosome in any form. IV exosome has no therapeutic evidence base, FDA enforcement actions, and a documented bacterial infection cluster. We would not recommend it at any clinic.

Does exosome replace minoxidil and finasteride?

No. First-line AGA is minoxidil 5% + finasteride 1 mg (Chen 2020). Exosome scalp adjunct is preliminary (non-inferior to PRP, 'data lacking' per Kost 2022). Exosome sits on top of established therapy, never replaces it.

Exosome vs PRP?

PRP is autologous (your own blood). Exosome is allogeneic (donor MSC culture). Estupiñán 2025 split-face: exosome NON-INFERIOR to PRP, not superior. Counterfeit Korean exosome circulates — ask for direct-distribution documentation if pursuing elsewhere.

One-trip exosome course?

Single-session skin protocols viable in a 3-day trip. Full 5-session scalp AGA course requires monthly intervals × 5 months — NOT single-trip and cannot be compressed.

Most serious risks?

(1) IV / systemic injection sterility — FDA enforcement + bacterial infection cluster. (2) Hypersensitivity to MSC-derived material. (3) Counterfeit product without verifiable sterility.

Why cosmetic registration, not drug?

No exosome product has completed the multi-phase RCT efficacy / safety data required for drug approval. Cosmetic pathway permits topical application without that data. Until drug-grade RCT data is filed, exosome remains cosmetic-pathway.

Realistic improvement?

Modest, on top of baseline therapy. Acne scars: 12.6 percentage point delta vs control (Kwon 2020). Photoaging: GAIS improvement (Park 2023, subjective scale). Hair: non-inferior to PRP. We do NOT use 'regrow' / 'cure' / 'permanent' / 'miracle' language.

Safety — systematic review evidence?

Topical safety signal is more favorable than IV. Total exposed-patient count is small. Queen & Avram 2024: 9 alopecia studies, 125 patients, 10 serious adverse events across broader dermatology literature.

Pricing in Seoul?

Delight does not offer it. Market reference (other clinics): skin adjunct ~₩300,000-₩600,000/session; scalp single ~₩200,000-₩600,000; 5-session package ~₩1,500,000-₩2,500,000.

Exosome for melasma?

Preliminary adjunct evidence only. Foundation remains topical therapy + strict SPF + trigger avoidance. We would not offer exosome as melasma standalone.

Why does Delight refuse exosome protocols?

Small RCT base, modest effect sizes, no drug approval, unsettled long-term safety. We prefer modalities with deeper evidence support. May change as evidence matures.

Notice

Tell the dermatologist at consultation if any of the following apply.

Delight does not currently offer exosome therapy — this page is educational reference only
Pregnancy or breastfeeding
Active skin infection or HSV at the site
Active skin malignancy, autoimmune flare, or systemic immunosuppression
Stem-cell therapy framing or refusal of first-line treatments — we decline that framing
Counterfeit-product concern from prior overseas exosome — clinical safety review at consult

For your visit

Delight does NOT offer exosome. If traveling to Seoul specifically for exosome, this is not the clinic.
If seeking exosome elsewhere: 5-session scalp course requires monthly intervals over 5 months (NOT single-trip). Skin paired adjunct can fit a 3-5 day trip but full 3-session course requires multiple trips.
IV exosome caution: no therapeutic evidence base, documented safety concerns. Cross-check any clinic marketing IV exosome.
Multi-language consultation available; we discuss procedures we DO offer.

References

The clinical claims on this page — device specs, efficacy timelines, safety profile — are supported by the primary sources below. Each citation links to the original paper or regulatory record.18 refs

[1]Exosome biogenesis, composition, and therapeutic potential — current state. Int J Mol Sci (Krylova) (2023).
[2]Mesenchymal stromal cell-derived extracellular vesicles — biogenesis and therapeutic application review. Cells (Hade) (2021).
[3]Topical penetration of UCB-MSC exosome — Korean evidence base. Cytotherapy (Kim) (2017).
[4]ADSC-Exos rescue UVB photoaging — MMP-1 and MMP-3 suppression preclinical. Stem Cell Res Ther (Liang) (2020).
[5]ADSC-Exos + fractional CO2 for atrophic acne scars — Korean RCT n=25 (32.5% vs 19.9% p<0.01). Acta Derm Venereol (Kwon) (2020).
[6]ADSC-Exos + microneedling for photoaging — Korean RCT n=28 GAIS improvement p=0.005. J Cosmet Dermatol (Park) (2023).
[7]Exosome split-face trial vs PRP for androgenetic alopecia — NON-INFERIOR (not superior). J Cosmet Dermatol (Estupiñán) (2025).
[8]Exosome for hair loss — narrative review concludes 'data lacking'. Skin Appendage Disord (Kost) (2022).
[9]Exosome for androgenetic alopecia — 15 preclinical + 1 clinical study systematic review. J Cosmet Dermatol (Gupta) (2023).
[10]Exosome in dermatology — 9 alopecia studies + 125 patients + 10 serious adverse events. Dermatol Surg (Queen & Avram) (2024).
[11]Minoxidil + finasteride combination superiority for androgenetic alopecia — RCT evidence. J Am Acad Dermatol (Chen) (2020).
[12]Microneedling + minoxidil superior to minoxidil alone for AGA — meta-analysis. J Cosmet Dermatol (Abdi) (2023).
[13]MISEV2023 — ISEV minimal information for extracellular vesicle characterization (international gold-standard criteria). J Extracell Vesicles (Welsh ISEV) (2024).
[14]ISEV position paper on mesenchymal stromal cell EV-based therapeutics — foundational regulatory framework. J Extracell Vesicles (Lener ISEV) (2015).
[15]FDA Public Safety Notification on Stem Cell and Exosome Products — December 2019. US FDA (Safety Notification) (2019).
[16]FDA Warning Letter — Evolutionary Biologics IV exosome enforcement. US FDA (Warning Letter December 2024) (2024).
[17]FDA Warning Letter — New Life Medical IV exosome enforcement. US FDA (Warning Letter September 2025) (2025).
[18]Consumer warning — unapproved stem cell and exosome products and the Nebraska 2019 bacterial infection cluster. US FDA (Consumer Alert) (2020).

Reviewed byDr. SangYoul Yun· Board-Certified Dermatologist · AAD International Fellow (IFAAD) · ASLMS Member · Former Director, Banobagi Dermatology · KHIDI-registered International Patient Institution· Last reviewed 2026-05-16

Related procedures

ProcedureHair Loss Treatment in Seoul | Diagnosis-First 5-Treatment MenuSpecialist-led hair loss care in Gangnam by a board-certified dermatologist. Drug therapy, scalp regeneration injections, and biostimulator protocols are sequenced after diagnosis — not as a one-size-fits-all package.

Notice: Individual results may vary depending on skin condition, treatment history, and recovery factors. All treatment plans are determined through individual consultation with a board-certified dermatologist. The information on this page is for reference only and does not constitute medical advice or guarantee specific outcomes.

Next Step

We don't offer exosome therapy — but we're happy to discuss which evidence-based alternative (PRP, Rejuran, or our hair-loss program) fits your concern.

Even a short first message can help you check suitability, timing, and what to compare next before you book.

Contact

WhatsApp LINE KakaoTalk